Optimization of Linezolid Treatment Regimens for Gram-Positive Bacterial Infections based on Pharmacokinetic/Pharmacodynamic Analysis

Abstract

Linezolid 600 mg q.12h is still the clinically recommended empirical dosage for Gram-positive bacterial infections. However, as bacterial MICs increase, 600 mg q.8h may be required to achieve better efficacy.